Authors
Latest:
Automated Contract Management Provides Substantial Benefits to Nektar TherapeuticsCLM Matrix system exploits Microsoft SharePoint platform
Latest:
Risky Business: What Life Sciences Need to Know About the US Foreign Corrupt Practices Act Before an AcquisitionNearly 30% of acquiring companies do not evaluate FCPA risks prior to an acquisition
Latest:
PRIMES: The six key elements of successful drug/device developmentGuidance for companies starting out on the commercialization path
Latest:
Supreme Court: reverse payment settlements subject to antitrust scrutinyWhat are the risks of future 'pay for delay' settlements between branded and generic manufacturers?
Latest:
New cold chain solutions meet regulatory, shipper requirementsCold chain packagers balance cost, performance and compliance approaches
Latest:
Specialty Pharmacy: The Trends Shaping Best PracticesWhen it comes to navigating the complex clinical and commercial landscape for specialty drugs—including hurdles in access to these critical but costly therapies—today’s specialty pharmacies are bringing more skills and services to the table.
Latest:
Pharma ups the ante on DTC advertisingDespite the buzz around digital media channels, pharma continues to pour marketing dollars into television
Latest:
Managing government pricing programsWhen state and federal governments are involved, prices and reimbursements have both regulatory and financial consequences
Latest:
Getting products to market fast with the 3PL Title ModelA contractual arrangement that could save time and money for brand owners
Latest:
Evolving Patient Access Programs for Specialty TherapiesWhen a physician prescribes or treats a patient with your specialty drug, the stakes are high for everyone. Patient access is evolving to improve the patient and physician journey with specialty therapies
Latest:
Lessons learned on bona fide service fees and fair market value-is there a 'right answer'?Recent regulatory actions and court cases highlight the importance of due diligence in reporting the value of service fees when federal reimbursements are concerned. The financial consequences can be substantial
Latest:
Why community oncology mattersOncology is the market for today's pipeline products. Here's why the community setting needs to be preserved as a primary site of care to administer those products
Latest:
Machine learning finds purpose in commercial life sciencesMachine learning offers business knowledge based on the data that marketers and sales teams generate
Latest:
Data logging is not enough for a modern pharma supply chainIoT takes you from living in the past to shaping the future
Latest:
Connecting with physicians—and patients—at the point of careIntegrating pharma communications with electronic health-record systems brings value to patients and providers
Latest:
The Rising Importance of Observational ResearchInternational efforts to standardize guidelines for observational research could move the entire field forward
Latest:
Change is a constant for sales incentive planningSales Compensation Solutions, a new book from ZS Associates, outlines problems and solutions
Latest:
The Five Things We Need to Do to Re-invent Commercial OperationsBy running Commercial Operations like a stand-alone business, executives can sharpen their focus on strategy, tactics and overall performance
Latest:
Managing government pricing programsWhen state and federal governments are involved, prices and reimbursements have both regulatory and financial consequences
Latest:
The Rising Importance of Observational ResearchInternational efforts to standardize guidelines for observational research could move the entire field forward
Latest:
3PL selection as part of product launch processThe importance of partners being flexible and optimizing their processes in today's virtual climate
Latest:
Specialty pharmacy accreditation — burden and benefitAccreditation status is both an entry ticket and a competitive measure for specialty pharmacies to attract manufacturer attention
Latest:
Digital opinion leaders (DOLs) and their role in pharma marketsLike traditional thinking about key opinion leaders (KOLs) in healthcare, consider the DOL as part of a marketing campaign
Latest:
Focusing pharma marketing on 'headroom'In the race to improve product performance, not enough attention is paid to 'who's actually going to switch?'
